BLACK DIAMOND THERAPEUTICS, INC. Financials Black Diamond Therapeutics, Inc.
Equities
BDTX
US09203E1055
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.89 USD | +15.26% |
|
+11.98% | +109.61% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,154 | 193.1 | 65.46 | 145.1 | 309.4 | - | - |
| Enterprise Value (EV) 1 | 838.6 | -16.69 | -57.35 | 145.1 | 309.4 | 309.4 | 309.4 |
| P/E ratio | -15.6 x | -1.54 x | -0.71 x | -1.49 x | -3.44 x | -3.29 x | -3.03 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 79.5 x |
| EV / Revenue | - | - | - | - | - | - | 79.5 x |
| EV / EBITDA | -16,595,135 x | -1,524,466 x | -709,045 x | - | - | - | - |
| EV / FCF | -22.1 x | -1.88 x | -0.77 x | - | -3.58 x | -2.92 x | -2.32 x |
| FCF Yield | -4.53% | -53.3% | -130% | - | -28% | -34.3% | -43.1% |
| Price to Book | 3.76 x | 0.98 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 35,996 | 36,229 | 36,366 | 51,635 | 52,530 | - | - |
| Reference price 2 | 32.05 | 5.330 | 1.800 | 2.810 | 5.890 | 5.890 | 5.890 |
| Announcement Date | 3/25/21 | 3/17/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 3.893 |
| EBITDA | -29.28 | -69.52 | -126.7 | -92.32 | - | - | - | - |
| EBIT 1 | -29.33 | -69.57 | -126.9 | -92.83 | -86.46 | -95.83 | -123.7 | -148.1 |
| Operating Margin | - | - | - | - | - | - | - | -3,804.19% |
| Earnings before Tax (EBT) 1 | -35.26 | -67.25 | -125.6 | -91.17 | -82.44 | -94.12 | -117.4 | -136 |
| Net income 1 | -35.26 | -67.25 | -125.6 | -91.17 | -82.44 | -93.77 | -121.1 | -145.2 |
| Net margin | - | - | - | - | - | - | - | -3,730.49% |
| EPS 2 | -16.99 | -2.050 | -3.470 | -2.520 | -1.880 | -1.712 | -1.788 | -1.942 |
| Free Cash Flow 1 | -24.7 | -52.29 | -102.9 | -85.27 | - | -86.5 | -106 | -133.5 |
| FCF margin | - | - | - | - | - | - | - | -3,429.23% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/20 | 3/25/21 | 3/17/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -35.32 | -25.96 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -35.36 | -26.08 | -25.68 | -23.17 | -22.12 | -21.85 | -21.56 | -20.03 | -24.01 | -20.86 | -22.88 | -23.56 | -24.24 | -24.99 | -33 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -35.08 | -25.87 | -25.51 | -22.93 | -21.65 | -21.08 | -20.88 | -19.15 | -23.01 | -19.41 | -22.64 | -23.21 | -23.79 | -24.48 | -33 |
| Net income 1 | -35.08 | -25.87 | -25.51 | -22.93 | -21.65 | -21.08 | -20.88 | -19.15 | -23.01 | -19.41 | -22.37 | -23.01 | -23.66 | -24.57 | -33 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.9700 | -0.7100 | -0.7000 | -0.6300 | -0.6000 | -0.5900 | -0.5700 | -0.5200 | -0.4500 | -0.3400 | -0.4350 | -0.4317 | -0.4267 | -0.4117 | -0.4900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/17/22 | 5/11/22 | 8/9/22 | 11/8/22 | 3/9/23 | 5/9/23 | 8/11/23 | 11/6/23 | 3/12/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 315 | 210 | 123 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -24.7 | -52.3 | -103 | -85.3 | - | -86.5 | -106 | -134 |
| ROE (net income / shareholders' equity) | - | -51.6% | -49.9% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -33.6% | -27.6% | -43.5% | - | - | - | - | - |
| Assets 1 | 105.1 | 244 | 288.7 | - | - | - | - | - |
| Book Value Per Share | -2.260 | 8.530 | 5.410 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.02 | - | 2.71 | 0.19 | - | - | - | 0.97 |
| Capex / Sales | - | - | - | - | - | - | - | 24.99% |
| Announcement Date | 3/24/20 | 3/25/21 | 3/17/22 | 3/9/23 | 3/12/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.89
USD
Average target price
12.8
USD
Spread / Average Target
+117.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +109.61% | 309M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BDTX Stock
- Financials Black Diamond Therapeutics, Inc.
